Virtual screening methods that complement HTS.

By F. Stahura, Jürgen Bajorath. 2004

108 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Molecular Docking and Structure-Based Drug Design Strategies (2015, background): “It can be regarded as the computational counterpart of experimental biological evaluation methods, such as high-throughput screening (HTS) [126].”
Virtual ligand screening: strategies, perspectives and limitations (2006, background): “Despite the fact that VS is still a young discipline, it has been reviewed frequently [22] [23] [24] [25] [26] [27] [28] [29] [30] , most recently in a comprehensive overview by Kubinyi [31] .”
Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. (2011, background): “However, while HTS involves the experimental screening of entire compound collections, VS consists of the computational evaluation of databases aiming to select a small number of reliable and experimentally testable candidate compounds that have a high probability of being active [5].”
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling (2007, background): “Over the years, the pharmaceutical industry has learnt to accept that virtual screening methods can indeed be an efficient complement to HTS (Stahura and Bajorath, 2004) to the point that they have undoubtedly become an integral part of today’s lead generation process (Bajorath, 2002; Bleicher et al”